7
Registered trials
1
Recruiting
6
Unique sponsors
8
Unique IMPs
6
Commercial trials
Drug classes (ATC)
—
ATC code not specified
5
C
Cardiology (ATC C)
2
H
Endocrinology (ATC H)
1
Mechanism of action (INN-stem analysis)
Unknown / small molecule
7 substances
Receptor fusion protein
1 substance
Phase III:
3
Phase II:
3
Phase I (Other):
1
Phase III
3 trials-
RecruitingActelion Pharmaceuticals Ltd. CommercialMACITENTAN; SELEXIPAG; TADALAFIL, MACITENTAN
-
PendingTenax Therapeutics Inc. CommercialLEVOSIMENDAN
-
PendingFondation Hopital Saint Joseph AcademicARGIPRESSIN; NORADRENALINE TARTRATE
Phase II
3 trials-
EndedAcceleron Pharma Inc. CommercialSOTATERCEPT
-
EndedBayer AG CommercialIMP not specified
-
EndedTectonic Therapeutic Inc. CommercialTX000045
Phase I (Other)
1 trial-
EndedTectonic Therapeutic Inc. CommercialIMP not specified
Sponsor activity
| Sponsor | Type | Trials | Phases | Recruiting |
|---|---|---|---|---|
| Tectonic Therapeutic Inc. | Commercial | 2 | Phase I (Other), Phase II | 0 |
| Acceleron Pharma Inc. | Commercial | 1 | Phase II | 0 |
| Bayer AG | Commercial | 1 | Phase II | 0 |
| Actelion Pharmaceuticals Ltd. | Commercial | 1 | Phase III | 1 |
| Tenax Therapeutics Inc. | Commercial | 1 | Phase III | 0 |
| Fondation Hopital Saint Joseph | Academic | 1 | Phase III | 0 |
New trials by year
2022
2
2024
2